Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

s become a significant medical problem in hospitals, long-term care facilities and in the community. CDAD is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing C. difficile bacteria to flourish. Older patients in particular are at risk for CDAD, potentially because of a weakened immune system or the presence of underlying disease. Approximately two-thirds of CDAD patients are 65 years of age or older. Historically, approximately 20% to 30% of CDAD patients who initially respond to treatment experience a clinical recurrence.

IDSA 2011

The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brings together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The meeting showcases the latest news in the field of infectious diseases with emphasis on contemporary trends, including emerging infections, new diagnostic and therapeutic advances. IDSA 2011 takes place October 20-23 at the Boston Exhibition and Convention Center in Boston, Massachusetts. For more information, visit www.idsa2011.org.

About Optimer

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium diffi
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... Life Sciences Holdings, Inc. (OTC Bulletin ... in the discovery, development and commercialization of novel drugs ... diseases, announced today that Dawson James Securities Inc., has ... report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial ...
... 2010 HealthLeaders-InterStudy, a leading provider of managed ... a shift toward coordinated patient care in Portland, ... to the Portland, Maine Market Overview, ... coordinated care models such as patient-centered medical homes ...
Cached Medicine Technology:Dawson James Initiates Research Coverage of Advanced Life Sciences 2Dawson James Initiates Research Coverage of Advanced Life Sciences 3Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps' Access to Physicians 2
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... Paso Robles, CA (PRWEB) March 28, 2015 ... damage restoration specialists , this week released a report ... worsen the symptoms of asthma sufferers, and according to ... healthy children. , According to the Environmental Protection ... can develop asthmatic reactions. Breathing in mold may trigger ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... of Matthew L. Myers, President, Campaign for ... following is a,statement of Matthew L. Myers, President, ... for Latin America and the world, both the,Mexico ... Tuesday,took significant action to reduce tobacco use and ...
... 2008) MIT graduate student and synthetic biologist ... pose threats to human health. His current mission: ... M.D. candidate and Ph.D. in the Harvard-MIT Division ... $30,000 Lemelson-MIT Student Prize for inventing processes that ...
... Bradley Kropp of Faculty of 1000 Medicine, researchers find ... of bowel function after gastrointestinal surgery a problem ... , Authors of the paper published in Urology evaluated ... them 5 pieces of chewing gum per day after ...
... TRAVERSE CITY, Mich., Feb. 27 Versus,Technology, Inc. ... its first fiscal quarter ended January 31, 2008, ... same quarter of the prior,year. Versus, quarterly revenues ... of major customer projects. Accordingly, the revenues,reported in ...
... by Swiss-Based In-House Counsel, To Proceed against Altria Group, Inc. and ... ... Inc., NEW YORK, Feb. 27 Broach & Stulberg, LLP announced,today ... for the Southern District of New York has denied motions to,dismiss age ...
... Feb. 27 To coincide with the annual,HIMSS ... announced a new release and new pricing of,its ... users,of EMR (Electronic Medical Records) software to scan ... package which is hosted on,Citrix(R) or Windows Terminal ...
Cached Medicine News:Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 2Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 2Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 4Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 2Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 3Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
... Dilutor-Dispenser is designed to transfer ... the clinical, biological, and chemical ... and performance as Gilsons other ... is ideal for routine laboratory ...
... synQUAD technology is a patented non-contact dispensing ... with a microsolenoid valve and stage stepper ... of liquid onto various slides, plates, or ... well, coefficient of variation (CVs) are less ...
16 channel Parallel dispenser using Positive Air Displacement Technology...
Medicine Products: